Medical device companies report sales increases in 2016

By Stewart Eisenhart, Emergo Group One third of all medical device companies participating in a recent Emergo industry survey reported sales increases of 10% or more for 2016. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not necessarily reflect those

Is health IT going to drink medtech’s funding milkshake?

Healthcare companies in the U.S. midwest last year brought in $1.7 billion in investments—an amount that came within $60 million of the all-time record set in 2014, according to the BioEnterprise Midwest Healthcare Growth Capital Report. Medical device companies took in the largest chunk of money, raising $696 million, or 40.3% of the total. But

Medtech stories we missed: Feb. 17, 2017

Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are medtech stories we missed this week, but were still worth mentioning. 1. Insulet touts glucose control study Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid

Why medtech companies should implement regionalized sales models

Having more flexibility in how sales roles are deployed and allowing more customization in regions represents the next frontier of productivity. Pete Masloski, ZS In today’s dynamic healthcare environment, IDN consolidation and centralized medical device purchasing are creating significant pricing pressure on the medical device industry. In fact, on average, prices for costly medical devices

S&P: Medtech outlook stable, even after downgrades

The outlook for investment-grade medical device companies remains stable even after a 3-year streak of 9 consecutive downgrades, according to a new report from S&P. The downgrade of investment-grade medical device companies was mostly caused by debt-financed mergers and acquisitions, according to S&P. Factors like changes in operating performance trends and financial policy also contributed

Medtech stories we missed: Feb. 10, 2017

From Glytec partnering to beat diabetes to Biolase, Gramercy Extremity Orthopedics and more getting FDA clearances, here are 7 recent medtech stories we missed this week, but were still worth mentioning. 1. BioTime proposes public offering of common stock Clinical-stage biotechnology company BioTech is intending to offer common stock shares in an underwritten public offering. BioTime focuses

Medtech stories we missed: Feb. 3, 2017

From disappointing Getinge earnings to a $2.25 billion U.S. Defense Department contract for Cardinal Health to a host of 510(k) clearances, here are seven recent medtech stories that are still worth a mention. 1. Getinge disappoints on earnings—again Getinge stock took a nearly 10% tumble last week after releasing earnings that Reuters says lagged analyst

Surmodics raises guidance, beats Q1 earnings

Shares in Surmodics (NSDQ:SRDX) rose today after the medical device maker met expectations on Wall Street with its fiscal 2017 1st quarter results. The Eden Prairie, Minn.-based company posted profits of $2.3 million, or 17¢ per share, on sales of $17.8 million for the 3 months ended Dec. 31, for bottom-line loss of -13.3% on

Trump and medtech: What people in the industry think

Many MDO and MassDevice readers think permanent medical device tax repeal should be a top priority for President Donald Trump and the Republican Congress. Many say the new administration will be good for medtech, too. Those were two of the major takeaways among nearly 100 MDO and MassDevice readers responding to an online survey. There are

Intuitive Surgical expects slowdown in da Vinci sales growth

Intuitive Surgical beat Wall Street expectations with its fourth quarter results, but company officials expect a slowdown in sales growth this year for da Vinci surgical robots. Intuitive Surgical earned $204 million, or $5.13 per share, off $386 million in sales during the three months ended Dec. 31, 2016, the company reported Tuesday evening. The fourth

Stryker Q4 earnings take hit from recalled hip implants

Stryker’s profits decreased 2.3% year-over-year in the fourth quarter, to $510 million, amid charges related to its recalled Rejuvenate or ABG II modular metal-on-metal neck hip stems, as well as expenses related to restructuring and acquisition costs. Earnings per share were $1.34, down 2.9%. Excluding the charges, Stryker’s profits would have been up 14.1% to $1.78

Donald Trump: 5 questions medtech needs to ask

From tax breaks to Obamacare repeal, medtech companies are likely due to experience major changes under President Donald Trump. The situation, though, remains unpredictable. “I don’t think that there has been a scenario, not since I’ve been a professional and in politics, where we really know so little about exactly what the key priorities are

Pages: 1 2 3 4 5 6

Healthcare IT funding hits record $5.1 billion

Global funding for healthcare information technology and digital health companies hit record levels last year, according to the latest annual report from Austin, Texas–based Mercom Capital Group. There were a record 622 deals worth $5.1 billion in 2016, up from 574 deals worth $4.6 billion in 2015, according to Mercom Capital Group. The amounts involve

Global CT systems market to quadruple by 2023

The market for computed tomography (CT) systems, which are used to generate detailed images of structures inside the body, is set to rise from just under $3.6 billion in 2016 to around $12.1 billion by 2023, representing a compound annual growth rate of 18.2%, according to research and consulting firm GlobalData. The company’s latest report

B Braun inks investment, cooperative deal with Trendlines Medical Sinagpore

B. Braun said today that it inked an investment and cooperation agreement with Trendlines subsidiary Trendlines Medical Singapore, making them a minority shareholder in the company. With the investment, B Braun will hold a 20.7% stake in the company, while Trendlines holds a 79.3% stake. “This agreement with B. Braun further advances our strategic relationship